ORIGINAL RESEARCH article
Front. Med.
Sec. Rheumatology
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1608085
BAFF/APRIL Expression-Guided Telitacicept Therapy Demonstrates Superior Efficacy in Systemic Lupus Erythematosus Patients: A Real-World Comparative Study
Provisionally accepted
- Nephrology Department, The First Affiliated Hospital of Army Medical University, No. 30 Gaotanyan Main Street, Shapingba District, Chongqing 400038, China, Chongqin, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Biological agents targeting B-cell pathways represent significant advances in systemic lupus erythematosus (SLE) management, yet optimal patient selection remains challenging. This study evaluated whether BAFF/APRIL expression testing could guide personalized treatment decisions in SLE patients.In this real-world observational study, we compared two treatment strategies in 86 SLE patients: personalized therapy with telitacicept in BAFF/APRIL double-positive patients (n=14) versus conventional belimumab therapy without expression testing (n=72). Clinical responses, laboratory parameters, and steroid-sparing effects were assessed at 3 and 6 months.Results: Despite having significantly higher baseline disease activity (SLEDAI 18.79±9.34 vs 8.86±4.3) and more severe proliferative lupus nephritis (Class IV/IV+V in 78.6% vs 52.8%), the BAFF/APRIL-guided telitacicept group achieved higher complete response rates (57.1% vs 48.6%) and lower non-response rates (7.1% vs 23.6%) compared to the conventional belimumab group.The BAFF/APRIL-guided group showed more substantial improvements in complement C3 levels (Δ=0.49 vs 0.24, p<0.001) and anti-dsDNA antibody reduction (Δ=-177.07 vs -117.00, p=0.028) at 6 months. Notably, normalization of immunological parameters was significantly better in the personalized therapy group, with dsDNA abnormalities decreasing from 92.9% to 7.1% (vs 91.7% to 32.5%) and C3 abnormalities from 100% to 28.6% (vs 91.7% to 61.1%). The BAFF/APRIL-guided group also achieved greater steroid dose reduction at 6 months (Δ=-35.00 vs -25.00 mg, p=0.014).BAFF/APRIL expression-guided telitacicept therapy demonstrated superior efficacy in improving clinical responses and laboratory parameters in SLE patients compared to conventional belimumab therapy, despite treating patients with more severe baseline disease. This real-world study provides preliminary evidence supporting BAFF/APRIL testing as a potential biomarker-driven approach for personalized SLE management, warranting further prospective validation.
Keywords: systemic lupus erythematosus, BAFF, April, Telitacicept, belimumab, personalized medicine, Biomarker-guided therapy
Received: 08 Apr 2025; Accepted: 25 Jun 2025.
Copyright: © 2025 Huang, Huang, Zeng, Zhang, Chen, Li, Zhao and Tang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Hongwen Zhao, Nephrology Department, The First Affiliated Hospital of Army Medical University, No. 30 Gaotanyan Main Street, Shapingba District, Chongqing 400038, China, Chongqin, China
Xiaopeng Tang, Nephrology Department, The First Affiliated Hospital of Army Medical University, No. 30 Gaotanyan Main Street, Shapingba District, Chongqing 400038, China, Chongqin, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.